期刊文献+

FLAG方案治疗儿童复发性急性淋巴细胞白血病及非霍奇金淋巴瘤短期疗效观察 被引量:5

The short-term efficacy of FLAG regime for relapsed childhood ALL and NHL
下载PDF
导出
摘要 目的观察FLAG方案治疗儿童复发性急性淋巴细胞白血病(ALL)及非霍奇金淋巴瘤(NHL)短期疗效及安全性。方法回顾性分析经FLAG方案[氟达拉滨30 mg/m2,d 1~5,阿糖胞苷2 g/m2,d 1~5,粒细胞集落刺激因子5μg/(kg.d)]治疗的19例复发性ALL和NHL患儿临床资料,其中ALL 15例(初诊时高危8例,中危2例,低危5例),NHL 4例(临床分期为Ⅳ期);早期复发12例,晚期复发7例。观察其疗效、生存时间及不良反应。结果经1个疗程后,11例(73.3%)ALL患儿达完全缓解(CR),其中高危5例,中危1例,低危5例;2例(50.0%)NHL患儿达CR;6例(50.0%)早期复发患儿达CR,7例(100.0%)晚期复发患儿均达CR,CR率明显高于早期复发患儿(P<0.05)。13例CR患儿,中位无病生存时间5.5个月(2~12个月)。血液学毒性Ⅳ级8例,Ⅲ级4例,Ⅱ级4例;合并感染13例(68.4%),均得到有效控制;肝脏毒性Ⅲ级1例,Ⅰ级2例,经治疗后均恢复。结论 FLAG方案治疗儿童复发性ALL及NHL疗效显著,尤其对于晚期复发患儿疗效较好;不良反应可以耐受。 Objective To evaluate the short-term efficacy and safety of FLAG regime for relapsed childhood acute lymphoblastic leukemia(ALL)and non-Hodgkin's lymphoma(NHL).Methods Retrospective analysis of 19 patients with relapsed ALL and NHL patients,including 15 patients with ALL(8 cases of high risk,2 cases of mode-rate risk,5 cases of low risk)and 4 patients with NHL(stage IV),was carried out.All patients were treated with FLAG regime[眼FLU 30 g/m2,d 1-5;Ara-c 2 g/m2,d 1-5;G-CSF 5 ug/(kg·d)].There were 12 early relapsed cases and 7 late-relapse cases.The efficacy,survival time and adverse events were recorded.Results After the first period of treatment,11(73.3%)patients with relapsed ALL achieved complete remission(CR),including 5 cases of high risk,1 case of moderate risk,and 5 cases of low risk;2(50%)patients with relapsed NHL(clinical stage Ⅳ)achieved CR.Among 13 CR patients,6(50%)cases were early-relapse and 7(100%)cases were late-relapse.The rate of CR was obviously higher in late-relapse cases than that in early-relapse cases(P 0.05).The disease free survival time of 13 CR patients was 2-12 months(median 5.5 months).The hematological toxicity was detected,8 patients were grade Ⅳ,4 patients were grade Ⅲ,and 4 patients were gradeⅡ.Thirteen(68.4%)patients had a combined infection after chemotherapy and it had been effectively controlled.The hepatotoxicity was detected,including 1 case of grade Ⅲ and 2 cases of grade I and had recovered.Conclusions It is showed that FLAG regimen can effectively treatment relapsed childhood ALL and NHL,especially for the late relapsed patients.The adverse events could be well tolerated.
出处 《临床儿科杂志》 CAS CSCD 北大核心 2011年第7期649-651,共3页 Journal of Clinical Pediatrics
关键词 氟达拉滨 急性淋巴细胞白血病 非霍奇金淋巴瘤 儿童 fludarabine acute lymphoblastic leukemia non-Hodgkin's lymphoma children
  • 相关文献

参考文献13

  • 1Hainsworth JD, Vazquez ER, Spigel DR, et ol. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network [ J ]. Cancer, 2008,112 (6) : 1288 - 195.
  • 2Ferrara F, Leoni F, Pinto A, et ol. Fludarabine, cytarabine, and granulocyte-colony stimulating factor for the treatment of high risk myelodysplastic syndromes [J]. Cancer, 1999,86(10) :2006-2013.
  • 3徐卫,李建勇,吴汉新,钱思轩,陆化,仇红霞,曹祥山,李丽,于慧,盛瑞兰.氟达拉滨治疗慢性淋巴细胞白血病41例临床观察[J].中华血液学杂志,2008,29(1):54-56. 被引量:2
  • 4顾龙君.儿童急性淋巴细胞白血病诊疗建议(第三次修订草案)[J].中华儿科杂志,2006,44(5):392-395. 被引量:476
  • 5Nguyen K, Devidas M, Cheng SC, et ol. Factors influencing survival after relapse from acute lymphoblastic leukemia : a Children's Oncology Group study [ J ]. Leukemia, 2008,22(12) :2142-2150.
  • 6World Health Organization. Handbook for reporting results of cancer treatment [ M ]. Geneva Switzerland : World Health Organization, 1979 : 15-22.
  • 7田怀平,卜书红,李方.氟达拉宾的药物学及应用[J].北京医学,2004,26(5):351-353. 被引量:4
  • 8Virchis A, Koh M, Rankin P, et ol. Fludarabine, cytosinearabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukemia or myelodysplastic syndromes [Jl. Br J Haematol, 2004,124(1 ) : 26-32.
  • 9Giebel S, Krawczyk-Kulis M, Adamczyk-Cioch M, et al. Fludarabine, cytarabine, and mitoxantrone (FLAM)for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Aduh Leuke-mia Group (PALG) [J]. Ann Hemotol,2006,85(10) : 717-722.
  • 10Lange BJ, Smith FO, Feusner J, et al. Outcomes in CCG- 2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group [J]. Blood,2008,111 (3) : 1044- 1053.

二级参考文献27

  • 1徐卫,李建勇,潘金兰,仇海荣,沈云锋,肖冰,陈丽娟,吴亚芳,盛瑞兰,薛永权.慢性淋巴细胞白血病的分子遗传学特点[J].中华肿瘤杂志,2006,28(5):349-352. 被引量:13
  • 2Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer, 1981, 48:198-206.
  • 3Grever MR, Kopecky KJ, Coltman CA, et al. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol, 1988, 30: 457-459.
  • 4Keating MJ, Kantarjian H, Talpaz M, et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood, 1989, 74 : 19-25.
  • 5Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med, 2000, 343:1750-1757.
  • 6O' Brien SM, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol, 2001, 19 : 1414-1420.
  • 7Keating M J, O' Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol, 2005, 23:4079-4088.
  • 8Stilgenbauer S, Dohner H. Molecular genetics and its clinical relevance. Hematol Oncol Clin North Am, 2004, 18:827-848.
  • 9Keating M J, Smith TL, Lerner S, et al. Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia. Leuk Lymphoma, 2000, 37: 71-85.
  • 10Gandhi V, Plunkett W. Cellular and clinical pharmacology of F-ara-A.Clin Pharmacokinet,2002,41:93 - 103.

共引文献482

同被引文献41

  • 1周海霞,李原,阮积晨,钱江潮,王菊香.大剂量阿糖胞苷治疗儿童白血病的不良反应防治[J].浙江医学,2005,27(4):299-300. 被引量:8
  • 2Luo S, Cai F, Jiang L, et al. Clinical study of Mito-FLAG regimen in treatment of relapsed acute myeloid leukemia [ J ]. Exp Ther Med, 2013, 5(3) : 982-986.
  • 3Kim H, Lee JH, Joo YD, et al. Prospective, multicenter, phase II study on reducing the dosage of idarubicin and FLAG for patients younger than 65 years with resistant acute myeloid leukemia: a comparison with a higher dosage trial [ J ]. Acta Haematol, 2014, 132(1): 87-96.
  • 4BECKER PS, MEDE1ROS BC, STEIN AS, et al. G-CSF Prim- ing, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm[J]. Am J Hema- tol, 2015, 90(4): 295-300.
  • 5ALWAN AF, MATFI BF, NAJI AS, et al. The efficacy of flu- darabine, high dose cytosine arabinoside with granulocyte colony stimulating factor (FLAG) protocol as salvage therapy for refracto- ry/relapsed acute leukemias in adult Iraqi patients[J]. Indian J Hematol Blood Transfus, 2014, 30(4): 231-235.
  • 6MAEDA Y, TERASAWA H, TANAKA Y, et al. Separate cellular localizations of human T-lymphotropic virus I(HTLV-1) Env and glucose transporter type I(GLUT1) are required for HTLV-1 Eov- mediated fusion and infection[J]. J Virol, 2015, 89(1): 502-511.
  • 7BORTHAKUR G, CORTES JE, ESTEY EE, et al. Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patientswith core binding factor acute myelogenous leukemia[J]. Am J Hematol, 2014, 89(10): 964-968.
  • 8SELMECZI A, UDVARDY M, ILLES A, et al. Treatment of a- cute myeloid leukemia a single center experience (2007-2013)[J]. Orv Hetil, 2014, 155(17): 653-658.
  • 9RABIZADEH E, PICKHOLTZ I, BARAK M, et al. Acute leukemia detection rate by automated blood count parameters and peripheral smear review[J]. Int J Lab Hematol, 2015, 37(1): 44-49.
  • 10VALENT P, BLATY K, EISENWORT G, et al. FLAG-induced remission in a patient with acute mast cell leukemia (MCL) ex- hibiting t (7;10)(q22;q26) and KIT D816H[J]. Leuk Res Rep, 2013, 3(1): 8-13.

引证文献5

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部